Oragenics, Inc. (NYSEAMERICAN:OGEN) Sees Significant Decrease in Short Interest

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totaling 57,838 shares, a drop of 46.5% from the December 31st total of 108,196 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average trading volume of 34,528 shares, the days-to-cover ratio is presently 1.7 days. Based on an average trading volume of 34,528 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.5% of the company’s stock are short sold.

Oragenics Price Performance

Shares of NYSEAMERICAN:OGEN traded up $0.02 during trading on Friday, hitting $0.84. 59,373 shares of the company were exchanged, compared to its average volume of 913,663. Oragenics has a 12-month low of $0.74 and a 12-month high of $18.90. The stock has a market capitalization of $3.59 million, a P/E ratio of -0.07 and a beta of 0.90. The firm’s 50 day moving average price is $0.87 and its 200-day moving average price is $1.10.

Oragenics (NYSEAMERICAN:OGEN) last released its quarterly earnings results on Friday, November 7th. The company reported ($1.96) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE boosted its stake in shares of Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after acquiring an additional 15,338 shares in the last quarter. Sabby Management LLC acquired a new position in shares of Oragenics in the third quarter valued at approximately $77,000. Finally, Clear Street LLC acquired a new stake in shares of Oragenics during the second quarter worth $270,000. Institutional investors and hedge funds own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.